Mydriacyl (Tropicamide)

Tropicamide competitively blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. By inhibiting these receptors, it prevents constriction of the pupil and relaxes the ciliary muscle, resulting in rapid dilation of the pupil and loss of accommodation. This pharmacologic effect allows better visualization of intraocular structures during diagnostic testing.

The specific dosing regimen for Mydriacyl is determined by the prescribing ophthalmologist based on the patient’s age, clinical indication, and response. Typically, one or two drops are instilled in the affected eye(s) and the effect is evaluated after a few minutes. Exact dose and frequency should follow the prescriber’s instructions.

Safety data for tropicamide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used during pregnancy or while breastfeeding if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Mydriacyl product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Tropicamide is a short‑acting antimuscarinic, producing pupil dilation within 15–30 minutes that typically resolves within 4–6 hours. Compared with longer‑acting agents such as phenylephrine or cyclopentolate, tropicamide offers a quicker onset and shorter duration, which can be advantageous for brief diagnostic procedures, though it may provide less profound dilation in some patients.

Mydriacyl should be stored at room temperature, below 25 °C, in its original container. The bottle must be kept tightly closed, protected from light and moisture, and out of reach of children. Do not freeze the solution, and discard any product that appears discolored or contains particles.

Mydriacyl is applied as an ophthalmic solution directly onto the conjunctival sac of the intended eye(s). The patient should be instructed to wash their hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops without touching the tip of the bottle to the eye or lashes. The eye may be gently closed for a few seconds to aid absorption.

The most serious adverse events include acute angle‑closure glaucoma, which presents as sudden eye pain, redness, blurred vision and halos, and requires immediate medical attention. Severe allergic reactions such as swelling, rash or urticaria around the eye are also critical. Persistent mydriasis and corneal edema, though rare, should be reported promptly.

Mydriacyl is contraindicated in patients with known hypersensitivity to tropicamide or any component of the formulation. It should be avoided in individuals with narrow‑angle or uncontrolled glaucoma, as pupil dilation can precipitate an angle‑closure attack. Caution is also advised for patients taking systemic anticholinergic medications or those with severe ocular surface disease.